Cardiovascular magnetic resonance signs of ischemia in hypertrophic cardiomyopathy.

[1]  M. Robson,et al.  Evidence for Microvascular Dysfunction in Hypertrophic Cardiomyopathy: New Insights From Multiparametric Magnetic Resonance Imaging , 2007, Circulation.

[2]  S. Nagueh,et al.  Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[3]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[4]  Carlos A. Dumont,et al.  Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance. , 2006, European heart journal.

[5]  F. Girolami,et al.  Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[6]  M. Borggrefe,et al.  CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis. , 2005, European heart journal.

[7]  S. Iliceto,et al.  Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. , 2005, Journal of the American College of Cardiology.

[8]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[9]  D. Pennell,et al.  Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I , 2005, Heart.

[10]  J. Schulz-Menger,et al.  Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. , 2005, Journal of the American College of Cardiology.

[11]  Olga Bondarenko,et al.  Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Dudley J Pennell,et al.  The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[13]  J. Schulz-Menger,et al.  Delayed Enhancement and T2-Weighted Cardiovascular Magnetic Resonance Imaging Differentiate Acute From Chronic Myocardial Infarction , 2004, Circulation.

[14]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[15]  I. Olivotto,et al.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[16]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[17]  J. Schulz-Menger,et al.  Detection of Acutely Impaired Microvascular Reperfusion After Infarct Angioplasty With Magnetic Resonance Imaging , 2003, Circulation.

[18]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[19]  Charles B. Higgins,et al.  Cardiovascular MRI and MRA , 2002 .

[20]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[21]  Wolfgang G Rehwald,et al.  Myocardial Magnetic Resonance Imaging Contrast Agent Concentrations After Reversible and Irreversible Ischemic Injury , 2002, Circulation.

[22]  W. Zheng,et al.  A malignant phenotype of hypertrophic cardiomyopathy caused by Arg719Gln cardiac beta-myosin heavy-chain mutation in a Chinese family. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[23]  W J McKenna,et al.  Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. , 2001, The American journal of cardiology.

[24]  G. Jensen,et al.  Sustained postinfarction myocardial oedema in humans visualised by magnetic resonance imaging , 2001, Heart.

[25]  C. Lorenz,et al.  Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. , 2001, Radiology.

[26]  Edwin Wu,et al.  Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction , 2001, The Lancet.

[27]  A E Arai,et al.  Magnetic resonance first-pass myocardial perfusion imaging. , 2000, Topics in magnetic resonance imaging : TMRI.

[28]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[29]  F. Schick,et al.  Conventional high resolution versus fast T(2)-weighted MR imaging of the heart: assessment of reperfusion induced myocardial injury in an animal model. , 2000, Magnetic resonance imaging.

[30]  W J McKenna,et al.  Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease , 2000, Heart.

[31]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[32]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[33]  O. Simonetti,et al.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. , 1999, Circulation.

[34]  P. Serruys,et al.  Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. , 1998, Circulation.

[35]  R. Kim,et al.  Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. , 1996, Circulation.

[36]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[37]  K. Bailey,et al.  Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. , 1995, Circulation.

[38]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[39]  P. Spirito,et al.  Natural history of hypertrophic cardiomyopathy. , 1994, British heart journal.

[40]  P. Rogan,et al.  A new missense mutation, Arg719Gln, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy. , 1994, Human molecular genetics.

[41]  D. Garcia-Dorado,et al.  Myocardial oedema: a preventable cause of reperfusion injury? , 1993, Cardiovascular research.

[42]  J. Gili,et al.  Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. , 1993, Cardiovascular research.

[43]  O. Ratib,et al.  Regional Myocardial Blood Flow and Glucose Utilization in Symptomatic Patients With Hypertrophic Cardiomyopathy , 1993, Circulation.

[44]  A. L'Abbate,et al.  Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. , 1991, Journal of the American College of Cardiology.

[45]  R. Bonow,et al.  Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. , 1985, Circulation.

[46]  R. Brasch,et al.  Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. , 1984, AJR. American journal of roentgenology.

[47]  J. Willerson,et al.  Abnormal myocardial fluid retention as an early manifestation of ischemic injury. , 1976, Recent advances in studies on cardiac structure and metabolism.

[48]  H. Blackburn.  Classification of the electrocardiogram for population studies: Minnesota Code. , 1969, Journal of electrocardiology.

[49]  Esko Vanninen,et al.  First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. , 2003, Radiology.

[50]  A. Tajik,et al.  Prevalence and Severity of “Benign” Mutations in the β-Myosin Heavy Chain, Cardiac Troponin T, and α-Tropomyosin Genes in Hypertrophic Cardiomyopathy , 2002, Circulation.

[51]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.

[52]  K. Takeda,et al.  Assessment of myocardial fibrosis in cardiomyopathic hamsters with gadolinium-DTPA enhanced magnetic resonance imaging. , 1998, Investigative radiology.

[53]  R. Edelman,et al.  Clinical magnetic resonance imaging , 1990 .